Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P45379
UPID:
TNNT2_HUMAN
Alternative names:
Cardiac muscle troponin T
Alternative UPACC:
P45379; A2TDB9; A8K3K6; O60214; Q99596; Q99597; Q9BUF6; Q9UM96
Background:
Troponin T, cardiac muscle, encoded by the gene with accession number P45379, is a pivotal component of the troponin complex. It plays a crucial role in muscle contraction by binding to tropomyosin, thus regulating the calcium-sensitivity of the actomyosin ATPase activity in striated muscles.
Therapeutic significance:
The protein is implicated in several forms of cardiomyopathy, including familial hypertrophic cardiomyopathy 2, dilated cardiomyopathy 1D, and familial restrictive cardiomyopathy 3. These associations highlight its potential as a target for therapeutic interventions aimed at mitigating heart disease.